Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug CLIO-8221 takes on advanced solid tumors in early trial

NCT ID NCT07300943

Recruiting now Disease control Sponsor: Callio Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental drug, CLIO-8221, in 306 adults with advanced solid tumors that have spread or cannot be removed. The first phase finds the safest dose, and the second phase checks how well the drug shrinks tumors. The goal is to control the disease, not cure it, and participants must have tried other treatments first.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • AlfredHealth

    RECRUITING

    Heidelberg, Victoria, 3084, Australia

  • DFCI

    NOT_YET_RECRUITING

    Boston, Massachusetts, 02215-5450, United States

  • Integrated Clinical Oncology Network Pty Ltd

    RECRUITING

    South Brisbane, Queensland, 4101, Australia

  • Linear Clinical Research Ltd

    RECRUITING

    Nedlands, Western Australia, 6009, Australia

  • MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

  • Peter Maccallum Cancer Centre

    RECRUITING

    Box Hill, Victoria, 3128, Australia

  • Royal Melbourne Hospital

    RECRUITING

    Melbourne, Victoria, 3052, Australia

  • START Mountain

    RECRUITING

    West Valley City, Utah, 84119, United States

  • START San Antonio

    RECRUITING

    San Antonio, Texas, 78229, United States

  • Sarah Cannon Research Institute 335 24th Avenue North, Suite 400

    RECRUITING

    Nashville, Tennessee, 37203, United States

    Contact Email: •••••@•••••

  • Scientia Clinical Research

    RECRUITING

    Randwick, New South Wales, 2031, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.